The CDC and FDA have approved new Pfizer vaccines and monoclonal antibody treatments for RSV, targeting pregnant women and "neonates" (newborns). Media coverage emphasizes a 57% reduction in hospitalization risk for infants. The marketing of these treatments is criticized for treating seasonal illnesses as pharmaceutical sales opportunities.
